[EN] 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-(1-HÉTÉROARYLPIPÉRAZIN-4-YL)MÉTHYL-1,4-BENZODIOXANE À UTILISER N EN TANT QU'ANTAGONISTES D'ALPHA2C
申请人:ORION CORP
公开号:WO2016193551A1
公开(公告)日:2016-12-08
Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.
[EN] PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ PYRAZOLE ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 吡唑类化合物及其制备方法和用途
申请人:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF
申请人:Hanmi Pharmaceutical Co., Ltd.
公开号:EP3480193A1
公开(公告)日:2019-05-08
The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-β, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.
Pyrazole derivative as ALK5 inhibitor and uses thereof
申请人:HANMI PHARMACEUTICAL CO., LTD.
公开号:US10954232B2
公开(公告)日:2021-03-23
The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-β, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.